These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 25482593)

  • 1. Risk of mucocutaneous toxicities in patients with solid tumors treated with sunitinib: a critical review and meta analysis.
    Abdel-Rahman O; Fouad M
    Expert Rev Anticancer Ther; 2015 Jan; 15(1):129-41. PubMed ID: 25482593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of mucocutaneous toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis.
    Abdel-Rahman O; Fouad M
    Expert Rev Anticancer Ther; 2014 Jun; 14(6):751-60. PubMed ID: 24666215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of mucocutaneous toxicities in patients with solid tumors treated with lapatinib: a systematic review and meta-analysis.
    Abdel-Rahman O; Fouad M
    Curr Med Res Opin; 2015 May; 31(5):975-86. PubMed ID: 25708852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
    Lee WJ; Lee JL; Chang SE; Lee MW; Kang YK; Choi JH; Moon KC; Koh JK
    Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of hematologic toxicities in cancer patients treated with sunitinib: a systematic review and meta-analysis.
    Funakoshi T; Latif A; Galsky MD
    Cancer Treat Rev; 2013 Nov; 39(7):818-30. PubMed ID: 23455076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis.
    Chu D; Lacouture ME; Weiner E; Wu S
    Clin Genitourin Cancer; 2009 Jan; 7(1):11-9. PubMed ID: 19213662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib: an updated systematic review and comparative meta-analysis.
    Abdel-Rahman O; Fouad M
    Crit Rev Oncol Hematol; 2014 Dec; 92(3):194-207. PubMed ID: 25028151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib.
    McLellan B; Kerr H
    Dermatol Ther; 2011; 24(4):396-400. PubMed ID: 21910797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Practical management of sunitinib toxicities in the treatment of pancreatic neuroendocrine tumors.
    Valle JW; Faivre S; Hubner RA; Grande E; Raymond E
    Cancer Treat Rev; 2014 Dec; 40(10):1230-8. PubMed ID: 25283354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of hypothyroidism in patients with cancer treated with sunitinib: a systematic review and meta-analysis.
    Funakoshi T; Shimada YJ
    Acta Oncol; 2013 May; 52(4):691-702. PubMed ID: 23282114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
    Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
    Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
    [No Abstract]   [Full Text] [Related]  

  • 12. Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib.
    Rosenbaum SE; Wu S; Newman MA; West DP; Kuzel T; Lacouture ME
    Support Care Cancer; 2008 Jun; 16(6):557-66. PubMed ID: 18274784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of sunitinib and SU12662 on dermatological toxicities in metastatic renal cell carcinoma patients: in vitro, in vivo, and outcomes investigation.
    Teo YL; Chong XJ; Chue XP; Chau NM; Tan MH; Kanesvaran R; Wee HL; Ho HK; Chan A
    Cancer Chemother Pharmacol; 2014 Feb; 73(2):381-8. PubMed ID: 24306119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib.
    Richards CJ; Je Y; Schutz FA; Heng DY; Dallabrida SM; Moslehi JJ; Choueiri TK
    J Clin Oncol; 2011 Sep; 29(25):3450-6. PubMed ID: 21810682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib.
    Lipworth AD; Robert C; Zhu AX
    Oncology; 2009; 77(5):257-71. PubMed ID: 19923864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blackberry-induced hand-foot skin reaction to sunitinib.
    Boone SL; Jameson G; Von Hoff D; Lacouture ME
    Invest New Drugs; 2009 Aug; 27(4):389-90. PubMed ID: 18998055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
    Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
    Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.
    Je Y; Schutz FA; Choueiri TK
    Lancet Oncol; 2009 Oct; 10(10):967-74. PubMed ID: 19767240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sunitinib: a cause of bullous palmoplantar erythrodysesthesia, periungual erythema, and mucositis.
    Suwattee P; Chow S; Berg BC; Warshaw EM
    Arch Dermatol; 2008 Jan; 144(1):123-5. PubMed ID: 18209189
    [No Abstract]   [Full Text] [Related]  

  • 20. The use of sunitinib in renal cell carcinoma: where are we now?
    Czarnecka AM; Szczylik C; Rini B
    Expert Rev Anticancer Ther; 2014 Sep; 14(9):983-99. PubMed ID: 25066545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.